About Fuji Pharma
Operations of Fuji Pharma
Fuji Pharma Co., Ltd. is a pharmaceutical company engaged in the development, manufacture, and marketing of ethical pharmaceuticals.
Since our establishment in 1965, under the corporate philosophy of "We help people lead healthy lives by offering excellent pharmaceuticals" and "Our corporate growth is proportional to our personal growth", we have contributed to society by providing pharmaceuticals that help people improve and overcome pain and disability.
About Women's Healthcare
We have focused on women's healthcare for more than 50 years. We have been providing a wide range of products for supporting women's lifestyles, including those for dysmenorrhea, endometriosis, pregnancy, childbirth, and menopause that are mainly prescribed by gynecologists.
We started with the manufacturing of hormone drugs, which are difficult to control, and developed new drugs. Through various challenges and expanding our lineup, we have now become the largest manufacturer in Japan in this field.
About Biosimilars
Biosimilars (BS), also known as "follow-on biologics", are pharmaceuticals that have the same quality, safety, and efficacy as the reference biologics and are developed by different manufacturers. Since 2018, we have been in an exclusive partnership with the Icelandic company Alvotech for the commercialization of several biosimilars in Japan, strengthening the development and marketing of biosimilars in Japan. By promoting biosimilars, we will contribute to the reduction of the economic burden on patients and the optimization of medical expenses.
About Global CMO
CMO is an abbreviation of "Contract Manufacturing Organization" and refers to the business of contracting and acting on behalf of pharmaceutical manufacturing. We aim to expand production and marketing not only in Japan but also globally, centering on its group company OLIC in Thailand. A wide variety of dosage forms can be manufactured in Thailand and Japan, and the collaboration between OLIC and Toyama Plant will enable us to meet various customer needs.
Fuji Pharma's Values (Strengths)
Fuji Pharma's strengths (values) can be summarized in the following four points.
Contribution to women's health issues
For nearly half a century, since we began marketing ethical pharmaceuticals for women in 1974, we have continued to take on the challenge of dealing with diseases specific to women.
The market for women's healthcare is considered to be smaller than other fields, and the number of companies entering the field is limited. In this context, we have been working in this field to respond to unmet needs with the belief of our company being uniquely capable of providing value.
Today, women's healthcare is one of our company's strengths, and we will continue to deepen our contributions in this area.
Manufacturing base for drug products with high barriers to market entry
We manufacture pharmaceuticals at two sites: Toyama Plant and OLIC in Thailand.
We have strengths in the production of drugs that are difficult to handle, such as sterile preparations and highly active pharmaceuticals, and have built a manufacturing base for products under strict quality control.
Hormone drugs used in women's healthcare, in particular, have a significant impact on the human body even in small amounts, so their manufacturing requires special equipment and specialized technology, making them an area with a high barrier to entry within the pharmaceutical industry.
We have been working in this field for many years, and this expertise is a great strength for us.
Experience in diverse research and development and production
We conduct pharmaceutical research and development primarily at the Toyama Research and Development Center and Tokyo Head Office. We have pursued a wide range of possibilities in pharmaceuticals, including new drugs, biosimilars, and generic drugs, regardless of genre. We will continue our research and development efforts to respond to the real needs of patients and healthcare professionals.
Management that values people first and foremost
Since our foundation, we have emphasized human capital management that values people based on the philosophy of "people first".
Based on the belief that the growth of each and every employee leads to the growth of the company, we have devoted ourselves to creating an environment in which employees can improve themselves through various challenges. We believe that the accumulated challenges and contributions of our employees lead us to realize our corporate philosophy of "Our corporate growth is proportional to our personal growth".
One of the mechanisms supporting this human capital management is our company's unique personnel evaluation system, called virtue-based evaluations.
Inspired by oriental thought, "virtue" in our company is defined as "doing one's best for others". This virtue is broken down into 7 items and 19 indicators, and employee behavior and attitude are reflected in the evaluation.
Through the practice of virtues, we believe that our attractiveness as employees and persons will increase, and that the increase in the number of such employees will lead to sustainable development by linking the growth of the entire organization with the enhancement of corporate value.
Domestic and Overseas Network
Our head office is located in Chiyoda-ku, Tokyo, and our domestic operations include the Toyama Plant and Research and Development Center in Toyama Prefecture. The pharmaceuticals produced are delivered to medical institutions nationwide through pharmaceutical wholesalers.
Overseas, we are expanding our business globally, mainly in ASEAN, with our group company OLIC in Thailand as the core.
About group company OLIC (Thailand) Limited
Founded: 1961
Location: Thailand
OLIC (Thailand) Limited is the largest contract manufacturer of pharmaceuticals in Thailand and provides contract manufacturing services to major global pharmaceutical companies. The company became a subsidiary of Fuji Pharma Co., Ltd. in 2012.
History of Our Company
Since our establishment, we have grown and contributed in a variety of ways.
You can find more information on our company's history on the following page.
Frequently Asked Questions about Fuji Pharma
1. What kind of company is Fuji Pharma?
Fuji Pharma Co., Ltd. is a pharmaceutical company engaged in the development, manufacture, and marketing of ethical pharmaceuticals.
Ethical pharmaceuticals are drugs that are prescribed after being examined by a doctor at a hospital or clinic and are different from general drugs sold over the counter at outlets such as drugstores. In addition, we do not offer door-to-door medicine box services, where households keep stocked medicines and pay only for what they use.
We are expanding our business not only in Japan but also overseas through OLIC in Thailand.
2. What areas of issues does the company focus on?
We are a pharmaceutical company that is tackling the two social issues of women's health and rising medical costs.
Our company has been focusing on women's healthcare for more than 50 years. We have developed a wide range of pharmaceuticals for women throughout their lives, including pregnancy and childbirth, menopause, and gynecological diseases.
In recent years, the issue of women's health has attracted attention as an issue for society as a whole, and the knowledge and efforts our company has cultivated over many years have become increasingly important.
In recent years, in addition to these areas, we have been focusing on biosimilars, which are expected to expand the options available to patients and curb rising medical costs, in order to realize sustainable medical care.
We will continue to provide pharmaceuticals that meet a wide range of social needs, with a focus on women's healthcare.
3. Are you a new drug manufacturer, or are you a generic drug manufacturer?
We are a specialty pharmaceutical company specializing in a particular field.
In the past, we have mainly manufactured and sold generic drugs, but we are also taking on the challenge of developing, manufacturing, and selling new drugs, mainly in the field of women's healthcare, which is one of our focus areas.
We will continue to take on the challenge of meeting unmet medical needs by expanding our lineup of new drugs, biosimilars, and value-added generic drugs, mainly in our focus areas.
4. What is your future direction?
We have formulated the Long-Term Vision 2035 "Always focusing on creating new value to women's healthcare and contributing to society where everyone can enjoy well-being" as the ideal image 10 years from now. As a strategy for the first five years to realize this vision, we have formulated the Mid-Term Business Plan (2025-2029).
